Eli Lilly plans API plant in Alabama to produce small molecule and peptide medicines, creating 450 jobs and enhancing U.S. pharmaceutical supply chains.

When referring to this article, please cite it as Hennessy, M. How Innovation and Risk Management Are Reshaping Modern Drug ...

This article is the second installment in our three-part series, Artificial Intelligence as Intellectual Property or “AI as IP™”, which explores ...

Large pharmaceutical conglomerate Eli Lilly has announced plans to build a $6 billion manufacturing facility in Huntsville, Alabama. The site will focus on the production of small molecules and ...

Agentic AI marks a major evolution in artificial intelligence, moving beyond reactive tools to autonomous systems that can ...

Eli Lilly and Company today announced plans to invest more than $6 billion in a new manufacturing facility in Huntsville, Alabama. This next-generation synthetic medicine active pharmaceutical ...

Cyber A.I. Group, Inc. ("CyberAI" or the "Company"), an emerging growth Cybersecurity, Artificial Intelligence and IT services company engaged in the development of next-generation market disruptive ...

AI in Healthcare Regulatory Affairs Market to reach USD 6.5 Bn by 2035 at 16.7% CAGR, driven by rising regulatory complexity and AI adoption.

India and Russia are poised to deepen their healthcare partnership, said Apollo Hospitals' Joint Managing Director Sangita Reddy, highlighting Russia's growing demand for Indian pharmaceuticals, ...

CHENNAI: The Russia–India Business Forum 2025, organised by the Roscongress Foundation and held in New Delhi in conjunction ...

Lilly’s planned Huntsville site is part of the drugmaker’s commitment to add four U.S. manufacturing sites through a $27 ...